AAPL   318.11 (+0.44%)
MSFT   181.81 (+0.13%)
FB   229.14 (-1.32%)
GOOGL   1,420.28 (-0.08%)
AMZN   2,410.39 (-0.47%)
NVDA   341.01 (-2.21%)
CGC   19.90 (-0.55%)
BABA   201.18 (-0.27%)
MU   49.45 (+7.97%)
GE   7.29 (+7.21%)
TSLA   820.23 (+0.17%)
AMD   52.74 (-0.85%)
T   31.85 (+3.34%)
ACB   15.30 (-1.99%)
F   6.03 (+3.25%)
GILD   74.92 (+2.38%)
DIS   121.53 (+0.48%)
NFLX   419.89 (+1.23%)
BAC   25.98 (+7.00%)
BA   149.52 (+3.31%)
AAPL   318.11 (+0.44%)
MSFT   181.81 (+0.13%)
FB   229.14 (-1.32%)
GOOGL   1,420.28 (-0.08%)
AMZN   2,410.39 (-0.47%)
NVDA   341.01 (-2.21%)
CGC   19.90 (-0.55%)
BABA   201.18 (-0.27%)
MU   49.45 (+7.97%)
GE   7.29 (+7.21%)
TSLA   820.23 (+0.17%)
AMD   52.74 (-0.85%)
T   31.85 (+3.34%)
ACB   15.30 (-1.99%)
F   6.03 (+3.25%)
GILD   74.92 (+2.38%)
DIS   121.53 (+0.48%)
NFLX   419.89 (+1.23%)
BAC   25.98 (+7.00%)
BA   149.52 (+3.31%)
AAPL   318.11 (+0.44%)
MSFT   181.81 (+0.13%)
FB   229.14 (-1.32%)
GOOGL   1,420.28 (-0.08%)
AMZN   2,410.39 (-0.47%)
NVDA   341.01 (-2.21%)
CGC   19.90 (-0.55%)
BABA   201.18 (-0.27%)
MU   49.45 (+7.97%)
GE   7.29 (+7.21%)
TSLA   820.23 (+0.17%)
AMD   52.74 (-0.85%)
T   31.85 (+3.34%)
ACB   15.30 (-1.99%)
F   6.03 (+3.25%)
GILD   74.92 (+2.38%)
DIS   121.53 (+0.48%)
NFLX   419.89 (+1.23%)
BAC   25.98 (+7.00%)
BA   149.52 (+3.31%)
AAPL   318.11 (+0.44%)
MSFT   181.81 (+0.13%)
FB   229.14 (-1.32%)
GOOGL   1,420.28 (-0.08%)
AMZN   2,410.39 (-0.47%)
NVDA   341.01 (-2.21%)
CGC   19.90 (-0.55%)
BABA   201.18 (-0.27%)
MU   49.45 (+7.97%)
GE   7.29 (+7.21%)
TSLA   820.23 (+0.17%)
AMD   52.74 (-0.85%)
T   31.85 (+3.34%)
ACB   15.30 (-1.99%)
F   6.03 (+3.25%)
GILD   74.92 (+2.38%)
DIS   121.53 (+0.48%)
NFLX   419.89 (+1.23%)
BAC   25.98 (+7.00%)
BA   149.52 (+3.31%)
Log in

NASDAQ:TECHBIO-TECHNE Stock Price, Forecast & News

$257.27
-3.38 (-1.30 %)
(As of 05/27/2020 04:00 PM ET)
Add
Compare
Today's Range
$245.46
Now: $257.27
$258.23
50-Day Range
$186.39
MA: $230.59
$279.56
52-Week Range
$155.17
Now: $257.27
$282.52
Volume291,700 shs
Average Volume249,712 shs
Market Capitalization$9.83 billion
P/E Ratio54.39
Dividend Yield0.49%
Beta1.11
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells biotechnology reagents, instruments, and clinical diagnostic controls worldwide. It operates in three segments: Biotechnology, Protein Platforms, and Diagnostics. The Biotechnology segment offers specialized proteins, such as cytokines and growth factors, immunoassays, antibodies, and related reagents to the biotechnology research community; and in situ hybridization, media, and other cell culture products and reagents. It also provides various products, which serves as predictive biomarkers and therapeutic targets for various human diseases and conditions, such as cancer, autoimmunity, diabetes, hypertension, obesity, inflammation, neurological disorders, and kidney failure. The Protein Platforms segment offers Biologics tools for researchers to interrogate protein purity and identify contaminants during the development and production of biologics; Western blot, an assay for protein analysis and identification; SimplePlex platform, an enzyme-linked immunosorbent assay for use in research and clinical diagnostics; and Single Cell Western platform to elucidate the properties of individual cells to understand cell behavior. The Diagnostics segment provides blood chemistry and gas quality controls, hematology instrument controls, diagnostic immunoassays, and other bulk and custom reagents for the in vitro diagnostic market. Bio-Techne Corporation has a strategic cooperation agreement with Micropoint Bioscience. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. It has strategic partnership with NanoString Technologies. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.
Read More
BIO-TECHNE logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.3Community Rank: 2.4Dividend Strength: 3.3Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.06 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryLife Sciences Tools & Services
SectorMedical
Current SymbolNASDAQ:TECH
CUSIP87837710
Phone612-379-8854

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$714.01 million
Cash Flow$5.76 per share
Book Value$33.78 per share

Profitability

Net Income$96.07 million

Miscellaneous

Employees2,250
Market Cap$9.83 billion
Next Earnings Date8/4/2020 (Estimated)
OptionableOptionable

Receive TECH News and Ratings via Email

Sign-up to receive the latest news and ratings for TECH and its competitors with MarketBeat's FREE daily newsletter.

BIO-TECHNE (NASDAQ:TECH) Frequently Asked Questions

How has BIO-TECHNE's stock been impacted by COVID-19 (Coronavirus)?

BIO-TECHNE's stock was trading at $180.58 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, TECH stock has increased by 42.5% and is now trading at $257.27. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of BIO-TECHNE?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BIO-TECHNE in the last year. There are currently 4 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for BIO-TECHNE.

When is BIO-TECHNE's next earnings date?

BIO-TECHNE is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for BIO-TECHNE.

How were BIO-TECHNE's earnings last quarter?

BIO-TECHNE Corp (NASDAQ:TECH) issued its earnings results on Thursday, April, 30th. The biotechnology company reported $1.39 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $1.15 by $0.24. The biotechnology company earned $194.70 million during the quarter, compared to the consensus estimate of $182.32 million. BIO-TECHNE had a return on equity of 13.04% and a net margin of 24.77%. The firm's quarterly revenue was up 5.3% on a year-over-year basis. During the same period in the previous year, the firm earned $1.21 earnings per share. View BIO-TECHNE's earnings history.

How often does BIO-TECHNE pay dividends? What is the dividend yield for BIO-TECHNE?

BIO-TECHNE announced a quarterly dividend on Tuesday, February 4th. Stockholders of record on Friday, February 14th will be given a dividend of $0.32 per share on Friday, February 28th. This represents a $1.28 annualized dividend and a yield of 0.50%. The ex-dividend date of this dividend is Thursday, February 13th. View BIO-TECHNE's dividend history.

What price target have analysts set for TECH?

10 brokerages have issued 12-month price targets for BIO-TECHNE's shares. Their forecasts range from $211.00 to $290.00. On average, they expect BIO-TECHNE's stock price to reach $243.22 in the next year. This suggests that the stock has a possible downside of 5.5%. View analysts' price targets for BIO-TECHNE.

Has BIO-TECHNE been receiving favorable news coverage?

Media stories about TECH stock have been trending negative this week, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. BIO-TECHNE earned a daily sentiment score of -2.9 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company's share price in the immediate future. View the latest news aboutBIO-TECHNE.

Are investors shorting BIO-TECHNE?

BIO-TECHNE saw a drop in short interest during the month of April. As of April 30th, there was short interest totaling 781,200 shares, a drop of 12.8% from the April 15th total of 896,000 shares. Based on an average trading volume of 238,200 shares, the short-interest ratio is presently 3.3 days. Approximately 2.1% of the company's shares are short sold. View BIO-TECHNE's Current Options Chain.

Who are some of BIO-TECHNE's key competitors?

What other stocks do shareholders of BIO-TECHNE own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BIO-TECHNE investors own include AbbVie (ABBV), NVIDIA (NVDA), Paychex (PAYX), Gilead Sciences (GILD), Johnson & Johnson (JNJ), Netflix (NFLX), Pfizer (PFE), Thermo Fisher Scientific (TMO), Advanced Micro Devices (AMD) and Amgen (AMGN).

Who are BIO-TECHNE's key executives?

BIO-TECHNE's management team includes the following people:
  • Mr. Charles R. Kummeth, CEO, Pres & Director (Age 59)
  • Mr. James T. Hippel, Sr. VP of Fin. & CFO (Age 48)
  • Ms. Brenda S. Furlow, Gen. Counsel, Sec. & Chief Compliance Officer (Age 61)
  • Mr. N. David Eansor, Pres of Protein Sciences Segment (Age 58)
  • Mr. Gerry Andros, VP of Sales and Marketing

What is BIO-TECHNE's stock symbol?

BIO-TECHNE trades on the NASDAQ under the ticker symbol "TECH."

Who are BIO-TECHNE's major shareholders?

BIO-TECHNE's stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (9.65%), Wellington Management Group LLP (4.08%), Brown Capital Management LLC (4.06%), Atlanta Capital Management Co. L L C (3.55%), Champlain Investment Partners LLC (2.86%) and State Street Corp (2.40%). Company insiders that own BIO-TECHNE stock include Brenda S Furlow, Charles A Dinarello, Charles R Kummeth, Harold J Wiens, James Hippel, John L Higgins, Norman David Eansor, Robert V Baumgartner and Roeland Nusse. View institutional ownership trends for BIO-TECHNE.

Which institutional investors are selling BIO-TECHNE stock?

TECH stock was sold by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Invesco Ltd., BlackRock Inc., Brown Capital Management LLC, Fred Alger Management LLC, Wellington Management Group LLP, Principal Financial Group Inc., and Schroder Investment Management Group. Company insiders that have sold BIO-TECHNE company stock in the last year include Brenda S Furlow, Charles R Kummeth, Harold J Wiens, James Hippel, John L Higgins, Norman David Eansor, Robert V Baumgartner, and Roeland Nusse. View insider buying and selling activity for BIO-TECHNE.

Which institutional investors are buying BIO-TECHNE stock?

TECH stock was acquired by a variety of institutional investors in the last quarter, including Ownership Capital B.V., Champlain Investment Partners LLC, FDx Advisors Inc., FDx Advisors Inc., Clearbridge Investments LLC, Massachusetts Financial Services Co. MA, First Trust Advisors LP, and Alyeska Investment Group L.P.. Company insiders that have bought BIO-TECHNE stock in the last two years include Charles R Kummeth, and Robert V Baumgartner. View insider buying and selling activity for BIO-TECHNE.

How do I buy shares of BIO-TECHNE?

Shares of TECH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is BIO-TECHNE's stock price today?

One share of TECH stock can currently be purchased for approximately $257.27.

How big of a company is BIO-TECHNE?

BIO-TECHNE has a market capitalization of $9.83 billion and generates $714.01 million in revenue each year. The biotechnology company earns $96.07 million in net income (profit) each year or $3.80 on an earnings per share basis. BIO-TECHNE employs 2,250 workers across the globe.

What is BIO-TECHNE's official website?

The official website for BIO-TECHNE is www.techne-corp.com.

How can I contact BIO-TECHNE?

BIO-TECHNE's mailing address is 614 MCKINLEY PLACE NE, MINNEAPOLIS MN, 55413. The biotechnology company can be reached via phone at 612-379-8854 or via email at [email protected]

This page was last updated on 5/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.